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Summary The monoclonal antibody 3F8 has been described as binding to the ganglioside GD2. This
antibody, of the IgG3 isotype, has been used in immunotherapy, radioimmunolocalisation and targeted
radiation therapy. 3F8 was originally observed to have a binding profile similar to two monoclonal antibodies,
UJ13A and 5.1 HI 1, characterised as binding to the neural cell adhesion molecule (NCAM). This observation
has also been confirmed using a hetero-antiserum prepared against purified NCAM. The cross-reactivity of
3F8 with NCAM has been confirmed by cross-blocking studies with an anti-NCAM antiserum, and by direct
immunoprecipitation and gel electrophoresis. In addition, we show that 3F8 binds to human NCAM from 3T3
fibroblasts transfected with NCAM cDNA constructs. It is possible that the common epitope shared by GD2
ganglioside and NCAM involves sialic acid residues common to both the ganglioside and the glycoprotein.
Monoclonal antibodies have been widely employed in the
search for tumour associated antigens. Many of these
reagents have been shown to react with carbohydrate
moieties associated with glycoproteins and/or glycolipids
(Magnani, 1984; Feizi, 1985; Feizi & Childs, 1985). Gang-
liosides, in particular, appear to be particularly good markers
for neuroectodermal tumours. GD2 for example is present on
human brain, but found in much higher amounts on
melanoma and neuroblastoma tissues (Cahan et al., 1982;
Schultz et al., 1984). Antibodies such as 3F8, recognised the
GD2 ganglioside (Cheung et al., 1985; Saito et al., 1985),
have been used for radioimmunoscintigraphy studies
(Cheung et al., 1986; Miraldi et al., 1986), and phase 1
clinical trials (Cheung et al., 1987). Melanoma and neuro-
blastoma patients have been given 3F8, either alone or con-
jugated to 131I and some clinical responses have been noted.
We became particularly interested in the expression ofGD2
as detected by monoclonal antibody 3F8, when it became
apparent that the staining pattern ofthe antibody was similar
to monoclonal antibodies UJ13A and 5.1.H11 (Kemshead,
1988) recently identified as binding to the neural cell
adhesion molecule (NCAM) (Patel et al., 1989a, b). In fact, a
variety of monoclonal antibodies to GD2 have been shown to
interfere with neuroblastoma and melanoma cell attachment
to various substrate adhesive proteins (Cheresh et al., 1986).
Cheresh et al. (1986) suggest that GD2 and GD3 play a role
in cell adhesion, excluding the possiblity that the reagents
studied are binding to glycoproteins.
We report here similarities in the staining profiles of 3F8
and an anti-NCAM antiserum and direct inhibition of 3F8
binding with the polyclonal antiserum. Monoclonal antibody
3F8 also immunoprecipitates a 145 kDa glycoprotein after
labelling of cellular glycoproteins with 35S methionine. In
addition, the monoclonal antibody binds to 3T3 cells trans-
fected with a human NCAM cDNA and Western blot
analysis shows that the antibody reacts with the 125 kDa
NCAM isoform in these cells.
Materials and methods
Cell lines
All cell lines, except those transfected with NCAM cDNAs
were grown at 37°C in a 6% CO2 incubator using RPMI 1640
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medium supplemented with 10% fetal calf serum (FCS)
(Gibco), 2mM glutamine (Gibco), 100 IU ml-' penicillin
(Gibco) and 100 fg ml-' streptomycin (Gibco) (complete
medium). Cells were harvested in their exponential growth
phase for subsequent studies. 3T3 fibroblasts transfected with
human NCAM cDNA were grown as described previously
(Gower et al., 1988).
Antibodies and indirect immunofluorescence
Monoclonal antibody 3F8 was raised following immunisation
of mice with neuroblastoma cells (Cheung et al., 1985). Two
preparations of antibody were used for these studies. One
was a purified fraction of ascites and the other concentrated
tissue culture supernatant from the hydridoma. Monoclonal
antibodies Thy-l (Cotmore et al., 1981), UJ13A (Allan et al.,
1983) and 5.1.H11 (Hurko & Walsh, 1983), were supplied as
purified antibodies from tissue culture supernatant (ICRF
central antibody service laboratory). The hetero-antiserum to
NCAM was raised by hyperimmunisation of rabbits with
purified mouse muscle NCAM (Moore et al., 1987).
A pellet of 106 cells or 6tsm cryostat sections were
incubated with either sufficient anti-NCAM antiserum or
antibody 3F8 to saturate antibody binding sites. After
washing twice with phosphate buffered saline containing 1%
FCS, the material was further incubated with an excess of
either fluorescein conjugated goat anti-rabbit Ig or sheep
anti-mouse Ig for 30 min. Cells/slides were subsequently
washed twice and examined using a Zeiss fluorescent micro-
scope with epi-illumination optics.
Cross-blocking studies
Some 2.5 x 105 JRI human rhabdomyosarcoma cells in 10 IL were plated into 96-well plates pre-blocked with protein.
Fifty "l of 1:10 dilution of rabbit anti-mouse NCAM
antiserum was added to the wells for 30 min. After washing
twice, as indicated above, 1251 labelled 3F8 (105
counts min-' well-') was added to the cells for a further
20min. The plates were washed free of unbound 3F8 and
material binding to the cell pellet estimated, using an LKB
Ultra-gamma counter.
Metabolic labelling and antigen extraction
Medium from an exponentially growing flask of SK-N-SH
neuroblastoma cells was replaced for 16 h with methionine
free medium supplemented with 35S methionine
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(150iLCi flaski'; 1000 Ci mmol '; Amersham), 10% FCS and
the additions listed above. After washing twice in PBS, cells
were resuspended to 3 x I07 cellsml-I in 100 mM Tris pH 7.5
containing 0.9% NaCl, 0.5% Nonidet P-40, 2mM
phenylmethylsulphonylfluoride (PMSF) and 10 igmlml
leupeptin, (lysis buffer) and lysed for 30 min at 4C. Follow-
ing centrifugation and pre-clearance with rabbit anti-mouse
Ig bound to Staphylococcus aureus (Staph. a.) different
amounts of either 3F8 or the hetero-antiserum were added to
the extract (3 x 106 cell equivalents) for 18 h. This was fol-
lowed with a further 60 min incubation with either Staph. a.
or Staph. a. pre-coated with rabbit anti-mouse Ig.
Immune complexes were pelleted by centrifugation and
washed four times with lysis buffer. The final pellet was
resuspended in 50 il of SDS-sample buffer (10 mM Tris/HCI,
pH 6.8, 10% glycerol and 2% SDS) and boiled for 3 min.
On some occasions, cells were incubated with antibody
before disruption in the lysis buffer. This was to allow cross-
linking of the antibody to the membrane antigen. Cross-
linking was achieved by incubating antibody coated cells in
2.0 ml of PBS (pH 8.3) containing 1 mM MgCl2, 0.02% NaN3
and 10 tLM dithiobis (succinimidyl propionate). After one
hour at room temperature, the cells were centrifuged and
resuspended in 100 mM Tris buffer pH 8.0 containing
140 mM NaCl. Following centrifugation, the cells were lysed
in NP40 containing buffer and the extracts treated as des-
cribed above.
SDS-page
Slab polyacrylamide gel electrophoresis was carried out ac-
cording to the method of Laemmli (1970). The gels were
stained with Coommasie Blue and impregnated with 'Amp-
lify'. Autoradiography was carried out at - 70°C using Fuji
RX X-ray film and intensifying screens. Autoradiograms
were developed 1-3 days after exposure to the gel.
Immunoprecipitation and Western blotting
Immunoprecipitation and Western blot analysis of 3T3
fibroblasts transfected with a cDNA coding for 125 kDa
human muscle NCAM isoform (G4 cells) was carried out
with monoclonal antibody 3F8 as described previously
(Gower et al., 1988).
Results
Binding ofan anti-mouse NCAM antiserum and monoclonal
antibody 3F8
We have compared the staining profiles of a rabbit anti-
mouse NCAM antiserum and monocolonal antibody 3F8 on
a variety of tissues and cell lines. Similar binding patterns
were identified on a variety of neuroectodermal and mesoder-
mal tissues. Neuroblastomas, Wilms' tumours, rhab-
domyosarcomas and Ewing's tumours stained equally well
with the anti-NCAM antiserum and the monocolonal
antibody 3F8 (Table I). Fetal brain and fetal muscle also
bound both reagents. Adult brain reacted with the hetero-
antiserum and monoclonal antibody 3F8 but no binding to
adult skeletal, smooth or cardiac muscle was observed. In
addition, fetal liver, adult liver, spleen, thymus and retina did
not bind either 3F8 or the anti-NCAM antiserum.
A high degree of concordance was also observed on
screening a variety of cell lines with both reagents. Both
monoclonal antibody 3F8 and the anti-NCAM antiserum
bound 6/8 human neuroblastoma lines tested (Table II). The
PCF and SK-N-LO lines did not bind either antibody,
although by other criteria these are clearly neuroblastoma
cell lines. In addition, the human rhabdomyosarcoma cell
line JRI bound both monoclonal antibody 3F8 and the
anti-NCAM antiserum. In the majority of these cell lines
more than 90% of cells bound the two reagents, although
there were differences in the intensity of staining noted. Less
than 20% of the neuroblastoma lines GOTO and NB1 bound
antibody 3F8. This compares to 90% of the cells binding the
anti-NCAM antiserum, which may again reflect quantitative
differences in the binding of the two antibody preparations.
In all cases binding was restricted to these primitive emb-
ryonic tumour cell lines as a variety of haemopoietic lines did
not bind either reagent (Table II). Similar results were
obtained using 3F8 obtained from either ascites or culture
supernatant. In addition, this data agrees with the specificty
of antibody 3F8 obtained in the neuroblastoma workshop
using a coded preparation of culture supernatant.
Anti-NCAM antiserum inhibits the binding ofmonoclonal
antibody 3F8 to the JRJ rhabdomyosarcoma cell line
To substantiate further that the monoclonal antibody 3F8
could bind to NCAM, blocking studies were undertaken.
Pre-incubation of JR1 cells with anti-NCAM antiserum (see
Figure 4) reduced the level of 3F8 binding (prepared from
either ascites or tissue culture fluid) to approximately 10% of
that seen in the control (Figure 1). As might be expected
preincubation of cells with an excess of monoclonal antibody
3F8 (ascites preparation) also inhibited the binding of
radiolabelled monoclonal antibody to the cell line. In con-
trast to these results, anti-NCAM antiserum did not block
the binding of two other monoclonal antibodies (UJ13A and
5.1.HlI) to JRI cells (Figure 1). Furthermore the antiserum
did not block the binding of an antibody to an irrelevant
Table I Reactivity of anti-NCAM antiserum and monoclonal
antibody 3F8 to tissues
Tissues Anti-NCAMa 3F8
Tumours
Neuroblastoma 4/4 4/4
Wilms' tumour 2/2 2/2
Medulloblastoma 1/1 1/1
Ewing's tumour 4/4 4/4
Rhabdomyosarcomas 6/6 6/6
Fetal tissues
Brain 1/1 1/1
Skeletal muscle 1/1 1/1
Heart muscle 0/1 0/1
Liver 0/1 0/1
Adult tissues
Brain 3/3 2/2
Skeletal muscle 0/2 0/2
Smooth muscle 0/2 0/2
Cardiac muscle 0/2 0/2
Liver 0/4 0/4
Thymus 0/1 0/1
aThe number of samples positive per number tested.
Table II Reactivity of anti-NCAM antiserum and monoclonal
antibody 3F8 against a variety ofhuman cell lines
Cell line Anti-NCAM 3F8
Neuroblastoma
Kellyc 2+ 3+
IMR32d 1+ 2+
SK-N-SHe 2+ 3+
PCFf - -
GOT09 I +
I +b
SK-N-LOh - -
NBli 2+ +b
CHP100 1+ 1+
Rhabdomyosarcoma
JRIk 2+ 3+
Haemopoietic
HL60' - -
K562m
CCRF-CEMn
aArbitary bindingunits: 3 +,strongly positive (>90% Cells binding
antibody); - Negative. bLess than 20% ofcellspositive. cSchwab etal.,
1983; dTumilowicz et al., 1970; eBiedler et al., 1973; fKemshead et al.,
1988; gSekiguchi et al., 1979; hSugimoto et al., 1984; 'Imashuku et al.,
1973;iSchlesinger et al., 1976; kClayton etal., 1986;'Collins etal., 1977;
mAndersson et al., 1979; nMorikawa et al., 1978.MONOCLONAL ANTIBODY 3F8 AND NCAM 863
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Figure I Anti-NCAM antiserum blocks the binding of 3F8 to target cells. 2 x 105 JRI rhabdomyosarcoma cells were incubated
for 30 min with either a hetero-antiserum to mouse NCAM or a non-immune serum (similar protein concentrations). After
washing, cells were further incubated with either 100,000 c.p.m. of '251 labelled monoclonal antibody 3F8 or a series of other
radiolabelled monoclonal antibodies. Monoclonal antibody binding to cells was assessed after washing using an LKB Ultragamma
counter. Results illustrate one experiment of three. Mean values of triplicate assay points presented. a, Cells pre-incubated with
non-immune serum and I25 antibody 3F8 (100% binding). b, Cells pre-incubated with 3F8 antiserum and '251 antibody 3F8. c,
Cells pre-incubated with an excess of anti-NCAM antiserum and '251 antibody 3F8. d, Cells pre-incubated with non-immune serum
and 1251 antibody S.I.HlI (anti-NCAM) (100% binding). e, Cell pre-incubated with 3F8 monoclonal antibody and 1251 antibody
S.R .H1 (anti-NCAM). f, Cells pre-incubated with non-immune serum and '251 antibody UJ13A (anti-NCAM) (100% binding). g,
Cells pre-incubated with 3F8 antiserum and '251 antibody UJ13A (anti-NCAM). h, Cells pre-incubated with non-immune serum
and 1251 antibody Thy-I (anti-Thy-l) (100% binding). i, Cells pre-incubated with 3F8 antiserum and '251 antibody Thy-I
(anti-Thy-I).
antigen (Thy-1) present on the JR1 cell line. In a further
series of blocking experiments we have confirmed that the
epitopes present on NCAM that are recognised by UJ13A,.
5.1.H1l, ERIC-1 and 3F8 are distinct (Patel et al., 1989a).
Biochemical characterisation of the binding ofmonoclonal
antibody, 3F8 to either neuroblastoma or rhabdomyosarcoma
cell lines
As has been previously reported, monoclonal antibody 3F8
binds to the ganglioside GD2 (Cheung et al., 1985). This we
have confirmed following chloroform:methanol:water extrac-
tion of glycolipids from rhabdomyosarcoma cells, thin layer
chromatography, immunoblotting with 1251 labelled 3F8
antibody and autoradiography (data not presented).
To determine if the epitope recognised by 3F8 involves
sialic acid sugar moieties, JR1 cells were treated with
neuraminidase. This reduced the level of radiolabelled
antibody 3F8 (from culture supernatant) binding to 20% of
the control as determined in a radiobinding assay. In con-
trast, no dimunition of monoclonal antibody 5.1.H11 binding
to JRI cells was observed after a similar treatment of cells
with neuraminidase (Figure 2).
Surface labelling of either the SK-N-SH or JRI cells with
15I using the lactoperoxidase technique (Marchalonis et al.,
1971), cell lysis in extraction buffer (0.1 M Tris'CI pH 7.4
containing 0.9% NaCl, 0.5% Nonidet P-40, 2 mM phenyl
methyl sulphonylfluoride), centrifugation ( x 100,000 g for
30min) and immuno-precipitation (Kemshead et al., 1983)
did not result in the identification of any glycoprotein bin-
ding to monoclonal antibody 3F8. A similar result was found
after Western blotting cell extracts (either NP40 or SDS
extracts) of either neuroblastoma or rhabdomyosarcoma
cells. However, after metabolically labelling neuroblastoma
cells with 35S methionine and immunoprecipitation with 3F8,
two major bands could be identified at 145 and 65 kDa along
with an occasional weak band at 120 kDa (Figure 3). The
145 and 120 kDa bands correspond to two of the isoforms of
NCAM often reported after immunoprecipitation with the
relevant antisera. Similar bands of 145 and 65 kDa were
identified following immunoprecipitation of 35S labelled JR1
extracts (data not shown). In addition, a similar band of
145 kDa was identified following cross-linking and
immunoprecipitation of-5 labelled cells, with an antiserum
to mouse NCAM (Figure 3).
In contrast to this, no bands at these molecular weights
were identified using either a control monoclonal antibody
(anti-Thy) known to bind to the human homologue of the
Thy-I antigen (Cotmore et al., 1981) or a non-immune rabbit
antiserum.
Reactivity of3F8 and 3T3 fibroblasts tran.sfected with human
NCAM cDNA
cDNA clones corresponding to the full coding sequence of
various NCAM isoforms from human muscle have recently
been isolated and placed in appropriate expression vectors
(Gower et al., 1988). Subsequently, the cDNAs have been
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Figure 2 3F8 binding is inhibited by neuraminidase treatment of
target cells. 5 x 106 JRI cells in I ml of 50 mm acetate buffer
pH 5.0 containing 150 mm NaCl were exposed to 1 IU ml-' of
neuraminidase (from Clostridium Perfingens) for 1 h at 37°C.
After washing x 2 with PBS containing 10% bovine serum
albumin, cells were incubated with an excess of monoclonal
antibody 3F8 for 30 min at room temperature. Excess antibody
was removed by washing x 2 and cells were incubated with
100,000 c.p.m. 1251 sheep anti-mouse Ig. Antibody binding to the
cells was determined after washing using an LKB Ultra-gamma
counter. Results illustrate one experiment of three. Mean values
of triplicate assay points presented. *, - neuraminidase; 0,
+ neuraminidase.
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Figure 3 Monoclonal antibody 3F8 binds to prote
and 65 kDa. The neuroblastoma cell line, SK
radiolabelled with 35S methionine as indicated in ti
and methods. Cells were disrupted with NP40 con
buffer and the cell extract incubated with either
antibody 3F8 or Thy-l. After a further incubation
anti-mouse Ig coated Staph. a. the immune com
boiled and the extract analysed by SDS polyacrylami
rophoresis. Gels were impregnated with 'An
autoradiography was carried out for 72h. a,
incubated with monoclonal antibody 3F8 (concentr
supernatant). b, Cell extract incubated with irrelevant
antibody Thy-1. c, Cell extract incubated with
NCAM antiserum (cross-linked to cells before lysis (se
d, cell extracts incubated with non-immune serum (crn
cells before lysis (see Methods)). Molecular weight sta
to calculate the size of the bands indicated: myosin 2C
galactosidase 116kDa; phosphorylase B 95 kDa; b
albumin 69 kDa.
transfected into 3T3 fibroblasts and permanei
obtained. One of these (called G4) which synth
kDa NCAM isoform (Gower et al., 1988) was
,
3F8 antibody binding. Control experiments show
fibroblasts did not express detectable levels
(Gower et al., 1988). NCAM could be immunc
from the G4 transfectants using an anti-hun
antiserum. When this material was subsequen
blotted protein bands of 110 and 125 kDa could
following incubation of the blots with the
antiserum (Figure 4a). Incubating similar blo
monoclonal antibody 3F8 also resolves a band
with weaker binding to the 110 kDa protein. Ir
the Blots with either an irrelevant monoclonal
non-immune antiserum gave no signal in the 1
range.
Discussion
Cross-reactions of monoclonal antibodies with
similar epitopes on different structures have be
previously. Usually carbohydrate epitopes ar
Whilst these cross-reactions mainly involve the
antibody they occassionally can be due to natural
anti-carbohydrate antibodies present to differini
different ascities preparations. To exclude the po:
the cross-reaction of the antibody 3F8 with NCA
these anti-carbohydrate specificities many of the
reported in the text have been undertaken wi
120 kDa
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Figure 4 Immunoprecipitation and Western blot analysis of
human NCAM transfected fibroblasts with monoclonal antibody
3F8. G4 cells expressing the 125 kDa glycosylphosphatidyl
inositol linked human NCAM isoform were grown in cell culture,
extracted with NP-40 and extracts immunoprecipitated with an
antiserum against human NCAM. Immunoprecipitates were run
on SDS gels and NCAM visualised after transfer to nitrocellulose
and blotting with either an antiserum to the molecule or monoc-
lonal antibody 3F8. a, Human NCAM in G4 cells visualised with
an anti-NCAM antiserum. b, Human NCAM in G4 cells
visualised with non-immune antiserum. c, Human NCAM in G4
cells visualised with monoclonal antibody 3F8. d, Human NCAM
cd in G4 cells visualised with an irrelevant monoclonal antibody c (M340).
in(s) of 145
-N-SH was prepared from both ascites and tissue culture fluid.
ie Materials The epitope on GD2 recognised by monoclonal antibody
taining lysis 3R8 involves sialic acid residues as demonstrated by the
motnhocrlobnbal inhibition of binding as a result of treatment of target cells
plexes were with neuramindidase. Sialic acids are linked by alpha 2-3
ide gel elect- and alpha 2-8 linkages in GD2. The latter linkage is
aplify' and generally not found in mammalian glycoproteins. However, it
Cell extract does occur in NCAM, a glycoprotein that is borth sialylated
ated culture and polysialylated on the extracellular portion of the
monoclonal molecule to varying degrees (Cunningham et al., 1983; Finne
anti-mouse et al., 1983)
e Method)). Cheresh et al. (1986) have proposed a role for GD2 in cell
oss-linked to adhesion since antibodies to GD2 interfere with cell attach-
D0 kDa; beta ment. In their study, they excluded the possibility of mono-
ovine serum clonal antibodies 3F8 and 126.4 (both anti-GD2) binding to
glycoproteins rather than GD2 on the basis that the
antibodies did not immunoprecipitate a protein from
nt cell lines metabolically labelled cells nor did they react by Western
esises a 125 blot analysis with any protein. While we would agree that
analysed for monoclonal antibody 3F8 does not immunoprecipitate
ved that 3T3 radioiodinated glycoproteins or identify proteins by Western
of NCAM blot analysis, our data show that the reagent recognises a
)precipitated 145 kDa glycoprotein following metabolic labelling of cell-
ian NCAM ular glycoproteins with 3"S methionine. The inhibition of cell
ktly Western adhesion seen with a variety of anti-GD2 antibodies, includ-
be identified ing monoclonal antibody 3F8 could, therefore, be due to a
anti-NCAM cross-reactivity with NCAM.
its with the Immunoprecipitation of 35S methionine labelled cell ex-
of 125 kDa tracts with monoclonal antibody 3F8 revealed two major
acubation of bands of 145 and 65 kDa and a minor band of 120 kDa. The
antibody or 65 kDa band is possibly a degradation product of NCAM
00-150 kDa (Hoffman et al., 1982). The 145 kDa and 120 kDa bands
correspond to two of the three isoforms of NCAM (reviewed
by Cunningham et al., 1987). We exclude the possibility that
GD2 exists in a complex with NCAM since it is likely that
the extraction conditions used would have disrupted
identical or lipid-protein interactions. Further confirmation that mono-
en reported clonal antibody 3F8 cross-reacts with NCAM was obtained
re involved. from immunoprecipitation and Western blot analysis of
monoclonal fibroblasts transfected with human muscle NCAM. Mono-
Ily occurring clonal antibody 3F8 binds to immunoprecipitated NCAM
g degrees in from 3T3 cells transfected with a human NCAM cDNA.
,ssibility that While the post-translational modification of human NCAM
iM is due to in 3T3 cells cannot fully mimic that which occurs in the
experiments muscle cell, sufficient glycosylation takes place to allow bind-
ith antibody ing of the 3F8 antibody and other anti-NCAM antibodiesMONOCLONAL ANTIBODY 3F8 AND NCAM 85
that are thought to bind to carbohydrate moieties (Patel et
al., 1989a). The glycosylation pattern of the transfected pro-
tein is not fully understood although the lack of binding of a
monoclonal antibody to alpha 2-8 polysialic acid chains
(greater than eight residues) would suggest that this
modification does not take place in 3T3 cells.
The fact that all three isoforms of NCAM are not detected
by monoclonal antibody 3F8 in JRI cell extracts might
reflect differential glycosylation of the three isoforms. Alter-
natively, it is known that the 145 kDa form of NCAM is the
earliest isoform expressed during embryogenesis (Levi et al.,
1987) and it is therefore, not surprising that the 145 kDa
isoform is predominantly detected in a primitive embryonic
tumour such as rhabdomyosarcoma. Northern blot analysis
of RNa extract from the SK-N-SH neuroblastoma and JRl
rhabdomyosarcoma cell line would suggest that this is the
case as a 6.7 kb mRNA representing the 145 kDa protein
(Dickson et al., 1987; Santoni et al., 1987; Small et al., 1987)
is detected with a human NCAM cDNA probe. In contrast,
cell lines which were negative for monoclonal antibody 3F8
and anti-NCAM antiserum staining did not contain NCAM
mRNA as detected by Northern blot analysis (data not
presented).
Other monoclonal antibodies which cross-react with
NCAM have been described. One of the best characterised is
the HNK-1 antibody (Abo & Balch, 1981). This antibody
appears to recognise a sulphated carbohydrate (Chou et al.,
1985, 1987; Shashoua et al., 1986) present on a number of
molecules involved in adhesion, including NCAM (Kruse et
al., 1984, 1985; McGarry et al., 1983). The HNK-1 deter-
minant is present on only 15-20% of all NCAM molecules
(Kruse et al., 1984). The epitopes recognised by monoclonal
antibodies 3F8 and HNK-1 are different since, in an inter-
national workshop on neuroblastoma, there was considerable
difference in the staining profiles of the two antibodies (Kem-
shead, 1988). Furthermore, the HNK-1 epitope differs from
that recognised by 3F8 in that it has been reported as not
involving neuraminic acid (Chou et al., 1985).
In conclusion, we have evidence that monoclonal antibody
3F8 reacts with NCAM in addition to its reactivity against
GD2. Since monoclonal antibody 3F8 has been used for
clinical trials on the basis that it was reactive against only
GD2, its binding specificity needs to be re-examined. Cross-
reactions should not necessarily deter the use of reagents
such as monoclonal antibody 3F8 for clinical purposes, but it
will be necessary to evaluate them fully so that accurate
binding profiles, affinity constants and antigen densities can
be compared and contrasted.
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